Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future

Xia Liao a, Yang Bu b, Qingan Jia c,*

a Department of Nutrition, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, China
b Department of Hepatobiliary Surgery, General Hospital, Ningxia Medical University, Yinchuan, 750001, China
c Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, China

Received 27 September 2019; received in revised form 23 October 2019; accepted 25 October 2019
Available online 2 November 2019

Abstract  Liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide. Western medicine and therapies are the primary treatment strategies of hepatocellular carcinoma (HCC), but the general prognosis for HCC patients is still dismal. Under these circumstances, HCC prevention is particularly important. Traditional Chinese medicine (TCM) encompasses a wealth of documented therapeutic resources, and “preventative treatment” is the principle of TCM. In China, TCM has been used for HCC prevention for thousands of years, and has also been demonstrated to be effective for the treatment of HCC in modern China. However, the TCM theory for prevention and treatment of HCC is more widely accepted in China than abroad. In this review, we first summarize the herbs and ancient formulas with therapeutic effects on HCC. We also review the research status of TCM in modern medicine as well as the current obstacles in its development. Finally, we discuss the future of TCM in the context of precision and integrated medicine. After reviewing the literature, we believe that TCM, through ancient development, is an advanced method of cancer treatment with positive curative effects, despite its surrounding controversy. Furthermore, precise analyses and systematic research methods provides novel approaches to modernize TCM for the future.

Copyright © 2019, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer deaths worldwide. Hepatocellular carcinoma (HCC) is the major histological subtype of primary liver cancers, accounting for 80% of the total liver cancer burden in the world. In China, HCC represents 50% of the diagnosed cases and deaths. HCC is associated with several risk factors—hepatitis viral infection, environmental toxins, oxidative stress, chronic inflammation, hepatotoxic drugs—and is involved in the development of chronic inflammation, fibrosis, and carcinogenesis. Western medicine and therapies are the primary strategies for the treatment of HCC (e.g., surgical resection, liver transplantation, radiofrequency, chemotherapy, and targeted molecular therapy), but the general prognosis for HCC patients is still dismal. With roots in ancient China, traditional Chinese medicine (TCM) has been used for the treatment of cancers, including HCC. TCM is based on empirically accumulated knowledge and has achieved curative effects. In modern China, TCM is the most widely used form of complementary and alternative medicine that benefits HCC patients, either alone or in combination therapies.

TCM encompasses a wealth of documented therapeutic resources, with two main parts: the TCM theoretical system and Chinese herbal medicine (CHM). "Preventive treatment" is the principle of TCM for controlling disease, which was recorded in Huang-di-nei-jing, the authoritative book of TCM written over 2000 years ago. Etiology is central to TCM theory which studies the zheng (syndromes) of cancers based on holism (the whole condition). In TCM theory, cancers are related to the disequilibrium of yin and yang and deficiency of vital qi (energy). Holism holds that the liver is the soul of the human body, which stores the blood, controls the sinews, and maintains a smooth and uninterrupted flow of qi. The causes of HCC are yu (stasis), du (toxicity) and xu (deficiency). Strategies of treatments include huo-xue-hua-yu (removing blood stasis), jian-pi-li-qì (regulating the flow of qi and strengthening the spleen), or qìng-re-jie-du (clearing heat and detoxifying). The system of TCM came into being in the Spring and Autumn period and reached its peak in the Song, Yuan, and Ming dynasties. Although TCM has been questioned throughout history and even neglected in modern times, it is an advanced method of cancer treatment. Chinese practitioners of TCM realize that, although not without some controversy, has positive curative effects. The system of TCM in ancient China, is an advanced method of cancer treatment that, although not without some controversy, has positive curative effects. Precise analysis and systematic research methods are still needed to verify the TCM theory.

History of TCM for HCC prevention and therapy

Classical herbal formulas, which were used for preventing and treating hepatic diseases thousands of years ago, are the most common application of TCM. Herbs were classified by function: toning qi, invigorating blood, nourishing yin, soothing liver qi stagnation, clearing heat, detoxifying, and dissolving stasis, all of which were potential sources for prevention and treatment of HCC. Although CHM has been demonstrated and documented to be effective for the treatment of HCC, critics point out that the toxicity of CHM is unclear. Also, the TCM theory for prevention and treatment is more widely accepted in China than abroad. Modern medicine requires a clear understanding of the effector compounds, toxic ingredients, and the associated signaling pathways of CHM. After years of research, great progress has been discerning the active compounds and associated signaling pathways in CHM. However, the active compounds are not a substitute for the complete CHM formula. TCM therapy treats HCC holistically, but the actual anticaner mechanism of the CHM formula is still unknown. In recent years, systems pharmacology, in particular, the subfield of network pharmacology, has emerged as a promising approach to elucidate the CHM's mechanisms of action and promote methodical drug discovery, thus facilitating the modernization of TCM.

Curative effects drove development of TCM for HCC in ancient times

Herbs for prevention and therapy of HCC

TCM covers thousands of species of plants, and for HCC therapy, many of these herbs are commonly used. The ten most commonly used herbs [Fuling (Poria), Huangqi (Astragali Radix), Bahnuhashsehcao (Hedyotidis Herba), Baizhu (Atractylodis Macrocephalae Rhizoma), Gancao (Glycyrrhizae Radix et Rhizoma), Baishao (Paenoniae Radix Alba), Chaihu (Bupleuri Radix), Denggui (Angelicae Sinensis Radix), Danshen (Codonopsis Radix), and Biejia (Trionycis Carapax)] affect huo-xue-hua-yu, jian-pi-li-qì, and qìng-re-jie-du. Additional herbs have been used for HCC therapy since ancient times, as detailed in Table 1.

Formulas for prevention and therapy of HCC

Formulas are the most common application of CHM, and some classical herbal formulas have remarkable prevention and treatment effects on HCC. Ren-shen-bie-jia-jian and xiao-chai-hu-tang are formulas used for inhibiting hepatocarcinogenesis through nourishing qi and soothing liver qi stagnation. In the TCM theory, the liver and kidney share the same origin, so the formulas of zi-yin-tang and fu-zheng-hua-yu-tang were used for prevention of HCC by toning the liver and kidney. Strengthening the spleen is another important principle for HCC therapy, and jian-pi-
The jie-du recipe was a famous herbal formula for strengthening the spleen and for detoxification. In addition to toning treatments, directly eliminating pathogenic factors is another principle of HCC using formulas such as qing-re-jie-du-tang and zao-lian mixture. Danshen and Jianghuang are anti-HCC herbs effective at inhibiting HCC by dissolving stasis. Additional formulas have been validated since ancient times, and details are described in Table 2.

The shortcomings of TCM theory and CHM

TCM practice relies on a combination of TCM theory and the personal experience of physicians, without standardized protocols for anti-HCC treatment. TCM theory is not widely accepted, which is a major obstacle for modernizing TCM. Molecular and cell biology in contemporary medicine have provided important insights into the pathogenesis of HCC and offer anti-HCC strategies. In addition, some toxic ingredients of CHM were reported, which further hindered the development of TCM. Therefore, exploration of the molecular signaling mechanisms of CHM as well as removal of toxic ingredients may provide support for the modern acceptance of TCM.

Application and research status of TCM for HCC patients in modern medicine

Status of CHM in HCC patients

CHM for HCC prevention. The cure rate of HCC is unsatisfactory, so prevention is particularly important. In China, TCM has long been used for HCC prevention and are viewed as effective preventative treatments. One clinical trial showed that the herb-derived compound oxymatrine had a hepatitis B virus-suppressing effect in 216 chronic hepatitis B patients. Glycyrrhizin and silymarin (also herb-derived compounds) have been demonstrated to reduce the incidence of HCC in patients with chronic hepatitis C virus infection and fibrosis. The classic formulas such as jian-pi-huo-xue and xiao-chai-hu-tang are also effective at inhibiting hepatocarcinogenesis in patients with hepatitis (B and C viruses) and cirrhosis.

CHM for anti-HCC therapy. Based on TCM theory, the clinical use of CHM is commonly prescribed as an herbal

---

**Table 1** Types of herbal treatments for HCC patients.

| TCM therapeutic principles | Herbs |
|----------------------------|-------|
| Supplemeting qi            | Baizhu (Atractylodis Macrocephalae Rhizoma), Huangqi (Astragali Radix), Danshen (Codonopsis Radix), Dansgui (Angelicae Sinensis Radix), Shanyao (Dioscoreae Rhizoma), Gancao (Glycyrrhizae Radix et Rhizoma), Baishao (Paenolae Radix Alba), Biejia (Trionycis Carapax) |
| Clearing heat and detoxifying | Baihuasheshecao (Hedyotidis Herba), Banzhilian (Scutellariae Barbatae Herba), Shengdihuang (Rehmanniae Radix), Zhizi (Gardeniae Fructus), Huangqin (Scutellariae Radix), Qinghao (Artemisiae Annuae Herba) |
| Invigorating blood and dissolving stasis | Ezhu (Curcumae Rhizoma), Danshen (Salviae Miltiorrhizae Radix et Rhizoma), Yuyin (Curcumae Radix), Tubiechong (Eupolyphaga Steleophaga) |
| Percolating dampness        | Fuling (Poria), Yiylren (Coicis Semen), Yinchen (Artemisiae Capillaris Herba), Cheqianzi (Plantaginis Semen), Yumixu (Maydis Stigma), Houpo (Magnoliae Officinalis Cortex), Dahuang (Rhei Radix et Rhizoma), Yuanhua (Genkwa Flos) |
| Rectifying qi               | Zhiqiao (Aurantii Fructus), Chenpi (Citri Reticulatae Pericarpium) |
| Releasing the exterior      | Chaihu (Bupleuri Radix), Guizhi (Cinnamomi Ramulus) |
Table 2  Types of herbal formulas for treatment of HCC patients.

| Herbal formulas          | Ingredients                                                                 | TCM therapeutic principles          | Provenance                      |
|--------------------------|-----------------------------------------------------------------------------|------------------------------------|---------------------------------|
| Shi-Quan-Da-Bu-Tang      | Renshen (Ginseng Radix et Rhizoma), Baizhu (Atractylodis Macrocephalae Rhizoma), Fuling (Poria), Gancao (Glycyrrhizae Radix et Rhizoma), Chuanxiong (Chuanxiong Rhizoma), Danggui (Angelicae Sinensis Radix), Shudihuang (Rehmanniae Radix Praeparata), Baisha (Paeoniae Radix Alba), Huangqi (Astragali Radix), Raugui (Cinnamomi Cortex) | Toning qi and blood                | Tai-ping-hui-min he-jii-ju-fang  |
| Xue-Fu-Zhu-Yu-Tang       | Chaihu (Bupleuri Radix), Gancao (Glycyrrhizae Radix et Rhizoma), Zhiqiao (Aurantii Fructus), Chuanxiong (Chuanxiong Rhizoma), Danggui (Angelicae Sinensis Radix), Shengdihuang (Rehmanniae Radix), Chishao (Paeoniae radix Rubra), Taoren (Persicai semen), Honghua (Carthami Flos), Niuxi (Achyranthis bidentatae Radix), Jieeng (Platycodonis Radix) | Promoting blood circulation and dissolving stasis | Yi-lin-gai-cuo                  |
| Xiao-Chai-Hu-Tang        | Chaihu (Bupleuri Radix), Huangqin (Scutellariae Radix), Shengjiang (Zingiberis Rhizoma Recens), Banxia (Pinelliae Rhizoma), Dazao (Jujubae Fructus), Danshen (Codonopsis Radix), Gancao (Glycyrrhizae Radix et Rhizoma) | Soothing liver qi stagnation, and balancing yin and yang | Shang-han-lun                   |
| Chai-Hu-Shu-Gan-Tang     | Chaihu (Bupleuri Radix), Chenpi (Citri Reticulatae Pericarpium), Zhiquiao (Aurantii Fructus), Xiangfu (Cyperi Rhizoma), Chuanxiong (Chuanxiong Rhizoma), Baisha (Paeoniae Radix Alba), Gancao (Glycyrrhizae Radix et Rhizoma) | Soothing liver qi, balancing blood, and relieving pain | Jing-yue-quan-shu               |
| Qing-Hao-Bie-Jia-Tang    | Qinghao (Artemisiae Annuae Herba), Biejia (Trionycis Carapax), Xishengdi (Rehmanniae Radix), Zhimu (Anemarrhenae Rhizoma), Mudanpi (Moutan Cortex) | Nourishing yin and refreshing liver | Wen-bing-tiao-bian              |
| Jia-Wei-Si-Jun-Zi-Tang   | Renshen (Ginseng Radix et Rhizoma), Baizhu (Atractylodis Macrocephalae Rhizoma), Huangqi (Astragali Radix), Fuling (Poria), Gancao (Glycyrrhizae Radix et Rhizoma), Baibiandou (Lablab semen Albam) | Toning spleen, nourishing qi, soothing liver qi, and dissolving stasis | San-yin-ji-bian-zhen-fang-lun    |
| Bu-Zhong-Yi-Qi-Tang      | Huangqi (Astragali Radix), Renshen (Ginseng Radix et Rhizoma), Shengma (Cimicifugae Rhizoma), Danggui (Angelicae Sinensis Radix), Gancao (Glycyrrhizae Radix et Rhizoma), Chenpi (Citri Reticulatae Pericarpium), Chaihu (Bupleuri Radix), Shengjiang (Zingiberis Rhizoma Recens), Dazao (Jujubae Fructus), Baizhu (Atractylodis Macrocephalae Rhizoma) | Invigorating spleen and stomach and toning qi | Pi-wei lun                      |
| Yi-Guan-Jian             | Beishashen (Glehniae Radix), Maidong (Ophiopogonis Radix), Danggui (Angelicae Sinensis Radix), Gouqi (Lycii Fructus), Shengdihuang (Rehmanniae Radix), Chuanlianzi (Toosendan Fructus) | Toning kidneys, nourishing qi and yin, and draining dampness | Xu ming-yi-lei-an               |
| Huang-Lian-Jie-Du-Tang   | Huanglian (Coptidis Rhizoma), Huangqin (Scutellariae Radix), Huangbo (Phellodendri chinensis Cortex), Zhizi (Gardeniae Fructus) | Clearing heat, Detoxification, and draining dampness | Wai-tai-mi-yao                  |
| Long-Dan-Xie-Gan-Tang    | Longdancao (Gentianae Herba), Zhizi (Gardeniae Fructus), Gancao (Glycyrrhizae Radix et Rhizoma), Shengdihuang (Rehmanniae Radix), Huangqin (Scutellariae Radix), Mutong (Akebiae Caulis), Zexie (Alismatis Rhizoma), Cheqianzi (Plantaginis Semen), Chaihu (Bupleuri Radix) | Clearing heat, detoxification, and draining dampness | Tai-ping-hui-min he-jii-ju-fang  |
formula, and Liao et al.\textsuperscript{35} reported 19.50\% outpatients with HCC received TCM services in Taiwan. For HCC patients in advanced stages ineffectively treated by Western medicine, \textit{xiao-ai-ping} or \textit{hua-chan-su} were always used as a monotherapy, and some patients had prolonged, stable disease or tumor shrinkage.\textsuperscript{36,37} Combination therapy is more common in clinical practice for HCC patients. The regimen of \textit{jian-pi-jie-du} granules combined with \textit{hua-chan-su} injection was associated with diminished risk when compared with transarterial chemoembolization (TACE) therapy in a small group of HCC patients.\textsuperscript{38,39} A combination of \textit{ai-di},\textsuperscript{40,41} \textit{hua-chan-su},\textsuperscript{42,43} and \textit{xiao-ai-ping} injection\textsuperscript{44} improved efficacy and reduced adverse reactions after TACE therapy for advanced-stage HCC patients.

**CHM for improving symptoms of HCC patients.** TCM is often considered as alternative therapy once HCC patients cannot benefit from radical therapy.\textsuperscript{7} Jineijin and Maiya were the most commonly used herbs for treating anorexia; Danshen and Huangqi for fatigue; Zhuru and Banxia for nausea and vomiting.\textsuperscript{45} Cancer pain is also a common complication of advanced-stage HCC. Chanwu powder and modified Jinhuang powder can be externally applied to alleviate cancer-induced pain. Also, topical application of Chanwu powder avoids some side effects and reduces the patient’s dependence on analgesics.\textsuperscript{46}

**Research status of anti-HCC mechanisms of TCM**

Diverse herbal formulas are commonly described in TCM theory. Herbs have many active components that make them effective.\textsuperscript{47} Many herbal formulas and their active ingredients are effective at inhibiting cell proliferation and inducing cell senescence, inducing apoptosis and autophagy, inhibiting metastasis and angiogenesis, improving drug resistance, and regulating immune function\textsuperscript{48} (Fig. 2).

**Inhibition of cell proliferation and induction of cell senescence.** HCC is characterized by uncontrolled cell proliferation.\textsuperscript{49} Formulas such as \textit{son-you-yin}\textsuperscript{12} and \textit{so-cheong-ryong-tang}\textsuperscript{50} as well as herbs including Danshen\textsuperscript{51} and Huangyaozi\textsuperscript{52} significantly inhibit cell proliferation and tumor growth in HCC. The compounds isolated from herbs Raddeanin A\textsuperscript{53} and Ardisupilloside-I\textsuperscript{54} also showed anti-proliferative effects in HCC cells. Cell senescence induction is a novel approach for HCC treatment.\textsuperscript{55} Ganoderiol F induces cell senescence by activating the extracellular-signal-regulated kinase (ERK) pathway and up-regulating the expression of p16.\textsuperscript{56} \textit{L. lucidum} Ait. fruit down-regulates retinoblastoma (RB) phosphorylation to induce cell senescence in HCC.\textsuperscript{57}

**Induction of apoptosis and autophagy.** Apoptosis is one of the most thoroughly studied cell processes in HCC.\textsuperscript{58,59} Many herbal compounds are effective at inducing apoptosis in HCC including Gypenoside, Isorhamnetin, Liquiritigenin, and N-Butylidenephthalide.\textsuperscript{60–63} Anoikis is another apoptotic process that occurs when a cell detaches from the extracellular matrix.\textsuperscript{64,65} Arecoline, Cuspidatum, Emodin, Polydatin, and Physcion induce anoikis through various related signaling pathways.\textsuperscript{66,67} Autophagy is a process that promotes cell death and is recognized as a target for HCC therapy because autophagy can contribute to anticancer therapeutic responses.\textsuperscript{68,69} Tetrandrine and Shikonin promote reactive oxygen species (ROS) generation and activate the ERK signaling pathway to induce autophagy in HCC cells.\textsuperscript{70,71} Conversely, Epigallocatechin-3-O-gallate strengthens

![Figure 2](image-url)  \textbf{Figure 2}  CHM herbal formulas contain multiple components to for holistic treatment. Herbal formulas are composed of many active components that make up the fundamental units of herbal action, such as the diverse mechanisms of anti-HCC formulas.
Traditional medicine for liver cancer

375

doxorubicin (DOX)-mediated anticancer effects in HCC cells, acting an autophagy inhibitor.72

Inhibition of metastasis and angiogenesis. Chinese herbal compounds have demonstrated potency in inhibiting invasion and metastatic potential in HCC.12 Artemisinin,73 Tanshinone IIA,74 and Resveratrol75,76 inhibit HCC metastasis through down-regulation of MMP2 and up-regulation of TIMP2 and E-cadherin. The combination of multiple herbal ingredients comprising astragalosides, Astragalus polysaccharide, and salvianolic acids inhibit TGF-β1-mediated invasion in HCC cells.77 Angiogenesis (the process of new blood vessels generating from existing vessels) plays a crucial role in tumor growth and metastasis and is a potential target for HCC therapy.78,79 Herbal formulas composed of cinobufotalin, Panax notoginseng saponins, ginsenosides Rg3, and lentinan inhibit angiogenesis as well as the expression of VEGF, EGFR, and MMP-2 in HCC.76,80 Gekko-sulfated glycopeptide decreases bFGF secretion and inhibits angiogenesis in HCC, acting through the heparin/heparan sulfate receptor.81

Improving drug resistance. Drug resistance is one of the characteristics of HCC contributing to the poor prognosis.82 Some herbal compounds have direct effects against drug resistance in HCC cells. Astragalus membranaceus polysaccharides enhance the anti-tumor effects of Adriamycin in HCC by up-regulating IL-2, IL-6, and TNF-α and down-regulating MDR1.83 Astragalside II, another component from A. membranaceus, is effective in enhancing the cytotoxicity of 5-fluorouracil (5-Fu) in HCC through the down-regulation of P-gp phosphorylation of ERK1/2 signaling.84 Ursolic acid also induces apoptosis in doxorubicin-resistant human HCC cells.85

Regulation of immune function. T-lymphocyte activation plays a pivotal role in HCC malignancy.86–88 Polysaccharides isolated from A. annua L increase CD4+ and CD8+ T cells, as well as IFN-γ and IL-4 secretion in HCC.89 Gastrodin up-regulates NF-κB, IL-2, and BCL-2 in CD4+ T cells and enhances cytotoxic activities of CD8+ T cells against HCC.90 Regulatory T cells (Tregs) function as negative immune regulators, and Astragalus polysaccharides inhibit FOXP3 expression and the proliferation of Tregs.81

Shortcomings of TCM for HCC treatment

Safety of TCM for HCC patients. CHM represents a huge and noteworthy reservoir for novel drug discovery, but CHM safety evaluation is necessary. Oral CHM formulas have developed rapidly, and their variety has increased. Many clinical studies by Chinese and Western medical researchers have verified the efficacy and safety of oral Chinese-patented medicines for liver cancer.92–95 In addition, much attention has been paid to the clinical application of CHM injections.96,97 However, the safety of CHM is still questioned because of the uncertainty of the ingredients in CHM, and the presence of toxic ingredients in CHM has also been reported.98 Aristolochic acid (AA), an abundant and possibly toxic compound in Aristolochia plants and various natural herbs, was widely implicated in HCC.99,100

Some researchers believe long-term use of CHM remains risky, and CHM still needs extensive basic and clinical experiments to evaluate safety.100,101

The efficacy of CHM in ant-HCC is still being questioned. Much progress of TCM has been made in the research of anti-HCC, and some clinical studies have encouraging results.102–106 However, some formulas worked well on HCC, but monotherapy or use of isolated ingredients weakened effects or had no impact entirely.107 The composition of CHM is very complex, and many bioactive components of CHM only exhibit powerful anticancer effects in vitro, or the anticancer effect is weak or lost when purified from the formula. Additionally, lack of high-level clinical research evidence severely limits the development of CHM.108

Molecular network integration to modernize TCM for HCC treatment

TCM formulas are composed of multiple herbs to achieve the highest efficacy with the fewest side effects for HCC prevention and treatment. Despite the widespread use of formulas in clinical practice of CHM, the combination principles based on the TCM theory were very challenging to discern. A variety of targeted molecular drugs have emerged in tumor therapy, but the limited efficacy shows that a single target is not enough to shift the outcome of HCC. Changing the focus of anti-tumor therapy from precision to integration should benefit patients, and we believe CHM has the inherent advantages for a multi-component strategy.109

TCM is a complex, mixed system with multiple components and multiple targets, and identifying potential bioactive molecules and the underlying mechanisms of combinations are essential tasks for TCM. Network pharmacology has emerged as a promising approach to accelerate drug development and elucidate the mechanisms of action of CHM and understanding the complex interactions among biological systems, drugs, and complex diseases.110,111 Network pharmacology provides a novel approach to promote drug discovery in a precise manner and at the systems level, modernizing TCM for the future.112,113 With the aid of systems pharmacology, the “drug-to-gene-to-target-to-disease subtype” network will be established, and the fang-ji design principles guided by TCM theory will be illuminated.

Conclusions and prospects

There are many obstacles to developing TCM in the context of modern medicine. Owing to its complexity, the holistic concept, and the study of zheng, TCM theory is often questioned; the unknown quality of herbs is a drawback for TCM; precise analyses needed for pharmacodynamic and toxicological mechanisms hinders the modern acceptance of TCM; and synergistic, additive, or antagonistic effects of the ingredients in CHM remains unclear. TCM views the human body as a complex, dynamic system and focuses on the balance of the human body, both internally and with its
external environment. Only by solving the issues mentioned above can TCM truly go global. TCM is an important feature of traditional Chinese culture. Like Zhaoyou Tang, an academician of the Chinese Academy of Engineering, described, "only when Western medicine learns from China can we create a new strategy for tumor therapy.”

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgement

This research project was mainly supported by the National Natural Science Foundation of China (81502694). This research project was also partly supported by the Fundamental Research Funds for the Central Universities (1191329835), Postdoctoral Science Foundation of China (2015M570330), and Key Projects of Ningxia Natural Science Foundation (N215130).

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2018;68(6):394–424.

2. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun. 2019;39(1):22.

3. Lange N, Dufour JF. Changing epidemiology of HCC: how to screen and identify patients at risk? Dig Dis Sci. 2019;64(4):903–909.

4. Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment of HCC. J Hepatol. 2018;69(2):525–533.

5. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA A Cancer J Clin. 2012;62(6):394–399.

6. Hu B, Wang SS, Du Q. Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: from bench to bedside. World J Hepatol. 2015;7(9):1209–1232.

7. Ling CQ, Fan J, Lin HS, et al. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. J Integr Med. 2018;16(4):236–248.

8. Liu X, Li M, Wang X, et al. Effects of adventuous traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine. 2019;62:152930.

9. Zeng Y, Shen Z, Gu W, Wu M. Inhibition of hepatocellular carcinoma tumorigenesis by curcumin may be associated with CDKN1A and CTGF. Gene. 2018;651:183–193.

10. Xi SY, Minuk GY. Role of traditional Chinese medicine in the management of patients with hepatocellular carcinoma. World J Hepatol. 2018;10(11):799–806.

11. Wang X, Wang N, Cheung F, Lao L, Li C, Feng Y. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. J Integr Med. 2015;13(3):142–164.

12. Jia QA, Ren ZG, Bu Y, et al. Herbal compound "Songyou Yin" renders hepatocellular carcinoma sensitive to oxaliplatin through inhibition of stemness. Evid Based Complement Altern Med. 2012;2012:908601.

13. Jia QA, Wang ZM, Ren ZG, et al. Herbal compound "Songyou Yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med. 2013;13:89.

14. Zhang Q, Zhang BH, Zhang KZ, et al. Moderate swimming suppressed the growth and metastasis of the transplanted liver cancer in mice model: with reference to nervous system. Oncogene. 2016;35(31):4122–4131.

15. Sun L, Fahey P, Zhu X, et al. A cohort study to examine the use of Chinese herbal medicine in combination with conventional therapies for patients with hepatocellular carcinoma in China. Integr Cancer Ther. 2018;17(3):902–911.

16. Zhai XF, Liu XL, Shen F, Fan J, Ling CQ. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: a randomized controlled study. Cancer. 2018;124(10):2161–2168.

17. Wang YM, Li YH, Xu ZY, et al. The effect of transarterial chemoembolization in combination with Kang’ai injection on patients with intermediate stage hepatocellular carcinoma: a prospective study. Integr Cancer Ther. 2018;17(2):477–485.

18. Tang C, Feng W, Qin L, Bao Y. Chinese herbal medicine, Jian pi Li Gan decoction, improved survival of nonresectable hepatocellular cancer after radiofrequency ablation: a retrospective study. Integr Cancer Ther. 2018;17(2):431–436.

19. Weng SW, Chen BC, Wang YC, et al. Traditional Chinese medicine use among patients with psoriasis in Taiwan: a nationwide population-based study. Evid Based Complement Altern Med. 2016;2016:3164105.

20. Chung VC, Wu X, Hui EP, et al. Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. Sci Rep. 2015;5:18111.

21. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52:i11–i18.

22. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:238–255.

23. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38(1):37–51.

24. Hu Y, Wang S, Wu X, et al. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma. J Ethnopharmacol. 2013;149(3):601–612.

25. Wu MC. Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems. Zhong Yi Yi Jie He Xue Bao. 2003;13(163–164.

26. Zhang XW, Liu W, Jiang HL, Mao B. Dissection of pharmacology-based study. J Integr Med. 2019;17(2):477–485.

27. Zhu H, Hao J, Niu Y, Liu D, Chen D, Wu X. Molecular targets of Chinese herbal medicine in combination with conventional therapies for patients with hepatocellular carcinoma in China. Integr Cancer Ther. 2018;17(3):902–911.

28. Zhai XF, Liu XL, Shen F, Fan J, Ling CQ. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: a randomized controlled study. Cancer. 2018;124(10):2161–2168.

29. Wang YM, Li YH, Xu ZY, et al. The effect of transarterial chemoembolization in combination with Kang’ai injection on patients with intermediate stage hepatocellular carcinoma: a prospective study. Integr Cancer Ther. 2018;17(2):477–485.

30. Tang C, Feng W, Qin L, Bao Y. Chinese herbal medicine, Jian pi Li Gan decoction, improved survival of nonresectable hepatocellular cancer after radiofrequency ablation: a retrospective study. Integr Cancer Ther. 2018;17(2):431–436.

31. Weng SW, Chen BC, Wang YC, et al. Traditional Chinese medicine use among patients with psoriasis in Taiwan: a nationwide population-based study. Evid Based Complement Altern Med. 2016;2016:3164105.

32. Chung VC, Wu X, Hui EP, et al. Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. Sci Rep. 2015;5:18111.

33. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52:i11–i18.

34. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:238–255.

35. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38(1):37–51.

36. Hu Y, Wang S, Wu X, et al. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma. J Ethnopharmacol. 2013;149(3):601–612.

37. Wu MC. Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems. Zhong Yi Yi Jie He Xue Bao. 2003;13(163–164.

38. Zhang XW, Liu W, Jiang HL, Mao B. Dissection of pharmacology-based study. J Integr Med. 2019;17(2):477–485.

39. Zhu H, Hao J, Niu Y, Liu D, Chen D, Wu X. Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. Sci Rep. 2018;8(1):7238.

40. Xu XL, Yang LJ, Jiang JG. Renal toxic ingredients and their toxicology from traditional Chinese medicine. Expert Opin Drug Metabol Toxicol. 2016;12(2):149–159.

41. Kalyan A, Kulik L. Multidisciplinary care in hepatocellular carcinoma: where do we go from here? Gastroenterology. 2017;152(8):1823–1825.

42. Lu LG, Zeng MD, Mao YM, et al. Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol. 2003;9(1):13431.

43. Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol. 2006;41(9):1087–1094.
Traditional medicine for liver cancer

32. Ferenci P, Scherer TM, Hofer H, Schniger-Hekele M, Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to antiviral combination therapy. J Hepatol. 2008;48: 528-528.

33. Zhang YH, Wu JP. Effects of Jian-Pi-Huo-Xue Formula on in patients with hepatitis, hepatic cirrhosis and low level of AFP. Zhong Xi Yi Jie He Nan Bao Zhi. 2000;10:13-14.

34. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular-carcinoma with shosaiko-to (T-9). Cancer. 1995;76(5):743-749.

35. Liao YH, Lin CC, Li TC, Lin JG. Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan. BMC Complement Altern Med. 2012;12.

36. Huang ZR, Wang Y, Chen JJ, Wang RP, Chen Q. Effect of Xiaoaiping injection on advanced hepatocellular carcinoma in patients. J Tradit Chin Med. 2013;33(1):34-38.

37. Meng Z, Yang P, Shen Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009;115(22): 5309-5318.

38. Zhai XF, Chen Z, Li B, et al. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integ Med. 2013;11(2):90-100.

39. Chen Z, Chen HY, Lang QB, et al. Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chememoablation in post-surgical patients with hepatocellular carcinoma: a case-control trial. Chin J Integ Med. 2012;18(5):339-344.

40. Gong XW, Yang QH, Wang XM, Xu YJ, Huang J. Aidi injection plus TACE for primary liver cancer: a Meta-analysis of randomized controlled trials. Zhonghua Zhong Yi Yi Jie He Za Zhi. 2012;12:1255-1258.

41. Zhou M, Higo H, Song H-Y, et al. Ligustrum lucidum Ait. fruit extract induces apoptosis in human Hep3B and HA22T tumour cells. BMC Complement Altern Med. 2012;12.

42. Dong Z, Chen Y, Mo C, et al. Meta-analysis of cinobufacin injection combined with transcatheter arterial chememoablation in treating primary liver carcinoma. Guangzhou Zhong Yi Yao Da Xue Xue Bao. 2016;33(2):274-280.

43. Li S, Zhao J, Liu J, et al. Prospective randomized controlled study of a Chinese herbal medicine compound Tanguz Yuyang Ointment for chronic diabetic foot ulcers: a preliminary report. J Ethnopharmacol. 2011;133(2):543-550.

44. Li CR, Xu F, Sun W. A randomized controlled clinical study of Xiaoaiping injection combined with hepatic arterial chememoabolation in the treatment of hepatocellular carcinoma. Zhongguo Yi Xue Qian Yan Za Zhi. 2015;7(12):84-87.

45. Liu X, Li N. Regularity analysis on clinical treatment in primary liver cancer by traditional Chinese medicine. Zhongguo Zhongyao Za Zhi. 2012;37(9):1327-1331.

46. Zhu SJ, Zhang FQ, Shi SZ. Clinical observation on Chanwusan granules combined with cinobufacini injection versus transcatheter arterial chememoablation in patients with hepatocellular carcinoma: a multicentre randomized controlled trial. Cancer. 1995;76(5):743-749.

47. Zhang YH, Wu JP. Effects of Jian-Pi-Huo-Xue Formula on the apoptosis and autophagy of HCC SMMC-7721 cells. Nat Cell Biol. 2006;79(12):1129-1139.

48. Hu B, Du Q, Deng S, et al. Ligusticum lucidum Ait. fruit extract induces apoptosis and cell senescence in human hepatocellular carcinoma cells through upregulation of p21. Oncol Rep. 2014;32(3):1037-1042.

49. Wang D, Song Q. Effect of levofloxoxacinone chalcone derivatives on the apoptosis and autophagy of HCC SMMC-7721 cells. Pak J Pharm Sci. 2017;30:1829-1832, 5(Special).

50. Janiszewska M, Poljak K. A confetti trail of tumour evolution. Nat Cell Biol. 2018;20(6):639-641.

51. Chen JC, Chung JG, Chen LD. Taxol induces apoptosis in human hepatocellular carcinoma cells through upregulation of p21. J Tradit Chin Med. 2013;33(1):34-38.

52. Meng Z, Yang P, Shen Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009;115(22): 5309-5318.
71. Gong K, Zhang Z, Chen Y, Shu H-B, Li W. Extracellular signal-regulated kinase, receptor interacting protein, and reactive oxygen species regulate shikonin-induced autophagy in human hepatocellular carcinoma. *Eur J Pharmacol*. 2014;738:142–152.

72. Chen L, Ye H-L, Zhang G, et al. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. *PLoS One*. 2014;9(1).

73. Tan W, Shen F, Luo X, et al. Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. *Phytotherapy*. 2011;18(2–3):158–162.

74. Xu Y, Tian F, Li R, Liu Z. Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. *Tumori J*. 2009;95(6):789–795.

75. Yu H-B, Pan C-E, Wu W-J, Zhao S-H, Huang C, Xu D, Xia Q, Wang P, Rong C, Su Y. Reversal of P-glycoprotein expression in human hepatocellular carcinoma. *J Biol Chem*. 2012;287(16):13206–13215.

76. Du Q, Chen YL. The effects of resveratrol on proliferation, apoptosis and invasion of Bel-7404 hepatocarcinoma cell line. *Fujian Yi Ke Da Xue Xue Bao*. 2007;41(6):509–513.

77. Liu X, Yang Y, Zhang X, et al. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell. *J Gastroeneterol Hepatol*. 2010;25(2):420–426.

78. Deng S, Hu B, An H-M, et al. Teng-Long-Bu-Zhong-Tang, a Chinese herbal formula, enhances antitumor effects of 5-Fluorouracil in CT26 colon carcinoma. *BMC Complement Altern Med*. 2013;13.

79. Bishayee A, Darvesh AS. Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy. *Curr Cancer Drug Targets*. 2012;12(9):1095–1118.

80. Chen T, Fu YL, Gong ZP, Deng LR, Hu YQ. Effects of Aristolochia contortae component and anticancer activity of green and ripe forsythiae fructus. *Am J Chin Med*. 2011;39(4):671–679.

81. Tian Q-E, Li H-D, Yan M, Cai H-L, Tan Q-Y, Zhang W-Y. Astragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice. *World J Gastroenterol*. 2012;18(47):7079–7086.

82. Huang C, Xu D, Xia Q, Wang P, Rong C, Su Y. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatocellular cancer cells by Astragaloside II. *J Pharm Pharmacol*. 2012;64(12):1741–1750.

83. Yang L, Liu X, Lu Z, et al. Uric acid induces doxorubicin-resistant HepG2 cell death via the release of apoptosis-inducing factor. *Cancer Lett*. 2010;298(1):128–138.

84. Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The Yin and Yang of evasion and immune activation in HCC. *J Hepatol*. 2015;62(6):1420–1429.

85. Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. *Gut*. 2019;68(5):916–927.

86. Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. *Cell*. 2017;169(7):1342–1356. e1316.

87. Chen J, Chen J, Wang X, Liu C. Anti-tumour effects of polysaccharides isolated from Artemisia annula L. by inducing cell apoptosis and immunomodulatory anti-hepatoma effects of polysaccharides. *Afr J Tradit, Complementary Altern Med*. 2014;11(1):15–22.

88. Shu G, Yang T, Wang C, Su H, Xiang M. Gastrodin stimulates anticancer immune response and represses transplanted H22 hepatic ascitic tumor cell growth: involvement of NF-kappa B signaling activation in CD4+ T cells. *Toxicol Appl Pharmacol*. 2013;269(3):270–279.

89. Li Q, Bao J-m, Li X-I, Zhang T, Shen X-h. Inhibiting effect of Astragalus polysaccharides on the functions of CD4(+) CD25(high)Treg cells in the tumor microenvironment of human hepatocellular carcinoma. *Chin Med J (Peking)*. 2012;125(5):786–793.

90. Mi CF, Yu SY. Clinical analysis of Huaier granule combined with CT-guided iodine-125 (125I) particles implantation for advanced hepatocellular carcinoma. *Zhongguo Shi Yong Yi Kan*. 2016;43(12):75–77.

91. Li JD, Peng Y, Dai Y. Clinical effects of Huaier and transarterial chemoembolization (TACE) in treatment of advanced hepatocellular carcinoma. *Xi Bu Yi Xue*. 2010;22(3):418–420.

92. Liu GF, Li F, Bi XJ, Zhu BH. Systematic review of clinical effects of Cidan capsules combined with TACE in treatment against primary liver cancer. *Zhong Guo Yi Yuan Yao Xue Za Zhi*. 2016;36(17):1496–1500.

93. Ma WH, LI N, Zou CP, Guo Y, An YH. Efficacy and safety of Milinlong capsule and transarterial arterial chemoembolization for primary hepatocellular carcinoma: a systematic review. *Shijie Ke Xue Ji Shu* Zhong Yi Yao Xian Dai Hua. 2016;18(4):692–698.

94. Yang R, Ding X. Study on the stability of 5 kinds of anti-tumor traditional Chinese medicine injection in infusion. *Zhongguo She Qu Yi Shi*. 2007;9(3):9.

95. He L, Cai Y, Xu YH, Hu HY. Research progress of anti-tumor mechanisms of traditional Chinese medicine injection. *Zhong Cheng Yao*. 2004;26(10):846–848.

96. Ng AWT, Poon SL, Huang MN, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. *Sci Transl Med*. 2017;9(412).

97. Zhang HM, Zhao XH, Sun ZH, et al. Recognition of the toxicity of aristolochic acid. *J Clin Pharm Ther*. 2019;44(2):157–162.

98. Cen XN. On the cancellation of the medicinal standards of Aristolochia contortae component and anticancer activity of green and ripe forsythiae fructus. *Am J Chin Med*. 2011;39(4):671–679.

99. Chen T, Fu YL, Gong ZP, Deng LR, Hu YQ. Effects of Aristolochia contortae component and anticancer activity of green and ripe forsythiae fructus. *Am J Chin Med*. 2011;39(4):671–679.
Traditional medicine for liver cancer

109. Khotskaya YB, Mills GB, Mills Shaw KR. Next-generation sequencing and result interpretation in clinical oncology: challenges of personalized cancer therapy. *Annu Rev Med*. 2017;68:113–125.

110. Berg EL. Systems biology in drug discovery and development. *Drug Discov Today*. 2014;19(2):113–125.

111. Zhang W, Huai Y, Miao Z, Qian A, Wang Y. Systems pharmacology for investigation of the mechanisms of action of traditional Chinese medicine in drug discovery. *Front Pharmacol*. 2019;10:743.

112. Azmi AS, Mohammad RM. Rectifying cancer drug discovery through network pharmacology. *Future Med Chem*. 2014;6(5):529–539.

113. Li H, Li T, Quang D, Guan Y. Network propagation predicts drug synergy in cancers. *Cancer Res*. 2018;78(18):5446–5457.